Real-Life Growth Hormone Treatment Patterns in Children from China: A Report from Two Databases.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this observational study publication.

The objective of this study is to investigate the real-world status of rhGH treatment in Chinese children with SS and its associated factors.

Who Took Part

PubMed indexes the participants as young children and children, both men and women.

This multicenter, retrospective, observational study included children treated with rhGH from January 1, 2017, to April 30, 2024, from two registry databases in China, which included children who were treated with at least one rhGH owing to GH deficiency (GHD), small for gestational age (SGA), or idiopathic short stature (ISS).

Data collected included baseline characteristics, the type of rhGH treatment [long-acting (LAGH) or short-acting (SAGH)], and treatment compliance.

How the Study Was Run

In design terms this was a multicenter study.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

What Was Measured

The subject headings attached to it are Human Growth Hormone, China, Growth Disorders, Infant, Small for Gestational Age, Databases, Factual, Body Height and Recombinant Proteins.

Author keywords: Growth hormone deficiency, Idiopathic short stature and Recombinant human growth hormone.

What This Means in Plain Language

The paper is a multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Advances in therapy), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.